FLT3 and acute myeloid leukemia: By integrating the mutation and transcriptome profiling of 14 FLT3-ITD AML patients with our cell-derived logic models, we were able to derive patient-specific signaling features and enable the identification of potential-tailored treatments restoring TKI resistance.